Continued sorafenib treatment inhibits tumor angiogenesis, resulting in a hypoxic environment within the tumor and facilitating the selection of resistant cell clones that attempt to adapt to oxygen and nutrient deprivation, leading to sorafenib resistance via the activation of HIF-1α and NF-κB in HCC [179]. This evidence concerns the gene HIF1A and neoplasm.